标题：格菲妥单抗 ，Glofitamab，CAS: 2229047-91-8，AntibodySystem Laboratories
货号：DHC90714
产品链接：http://www.atagenix.com/product_detail-75430.html
别名：Bispecific, CD20-TCB (2:1), RG-6026, CAS: 2229047-91-8
简介：Glofitamab (RO7082859) 是一种与 T 细胞结合的双特异性抗体，具有新颖的2:1 结构，B细胞上的CD20为二价，T细胞上的CD3为一价。Glofitamab 与恶性细胞上的CD20 结合后，可导致T细胞活化、增殖和肿瘤细胞杀伤。Glofitamab可诱导复发或难治性B细胞淋巴瘤的持久完全缓解。
货号：DHC90714
产品品牌：Antibodysystem
通用名：Glofitamab
纯度：>95% by SDS-PAGE.
浓度：1mg/ml
Formulationicon：0.01M PBS, pH 7.4.
内毒素：Please contact with the lab for this information.
别名：Bispecific, CD20-TCB (2:1), RG-6026
靶点;物种：Human CD20/MS4A1 & CD3E
种类：Humanized
受体鉴定：IgG1-kappa-lambda
CAS: 2229047-91-8
存储条件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
参考文献：
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. PMID: 36507690
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. PMID: 33739857
Glofitamab CD20-TCB bispecific antibody. PMID: 34263696
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. PMID: 34941996
Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. PMID: 35626120
Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab. PMID: 34953862
Engaging results with glofitamab. PMID: 33828233
Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. PMID: 35182296
Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma. PMID: 36078155
Engaging results with glofitamab in DLBCL. PMID: 36600006
Immunotherapy in indolent Non-Hodgkin's Lymphoma. PMID: 35663281
Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era. PMID: 35928819
Bispecific antibodies for the treatment of lymphomas: Promises and challenges. PMID: 34105818
Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting. PMID: 36895020
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. PMID: 34491877
[Current status and future prospects of diffuse large B-cell lymphoma treatment]. PMID: 36198538
Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody. PMID: 36726938
Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. PMID: 34768899
Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model. PMID: 33406104
Obinutuzumab-induced acute thrombocytopenia: Report of two cases and review of literature. PMID: 37143375
Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform. PMID: 36637189
